Non Small Cell Lung Cancer Clinical Trials in San Francisco, California

16 studies are recruiting for non small cell lung cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, San Francisco, California
    Locations
    328 in total
    Run by
    AstraZeneca

    See if you can join NCT06692738 on ClinicalTrials.gov

  2. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab mon…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    San Francisco Oncology Associates ( Site 0066), San Francisco, California
    Locations
    269 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06312137 on ClinicalTrials.gov

  3. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

    Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of California San Francisco, San Francisco, California
    Locations
    202 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT07195695 on ClinicalTrials.gov

  4. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California, San Francisco (UCSF), San Francisco, California
    Locations
    49 in total
    Run by
    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

  5. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

    The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Local Institution - 0159, San Francisco, California
    Locations
    326 in total
    Run by
    Bristol-Myers Squibb

    See if you can join NCT06561386 on ClinicalTrials.gov

  6. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UCSF Helen Diller Family CCC, San Francisco, California
    Locations
    38 in total
    Run by
    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

  7. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    California Pacific Medical Center, San Francisco, California
    Locations
    280 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06793215 on ClinicalTrials.gov

  8. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California San Francisco, San Francisco, California
    Locations
    38 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06343402 on ClinicalTrials.gov

  9. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California San Francisco, San Francisco, California
    Locations
    48 in total
    Run by
    Pierre Fabre Medicament

    See if you can join NCT04913285 on ClinicalTrials.gov

  10. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

    Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UCSF Medical Center-Mission Bay, San Francisco, California
    Locations
    118 in total
    Run by
    ArriVent BioPharma, Inc.

    See if you can join NCT07185997 on ClinicalTrials.gov

  11. Biomarkers for Risk Stratification in Lung Cancer

    This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary popula…

    Stage
    Not phased
    Ages
    40 and older
    Site
    Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California
    Locations
    3 in total
    Run by
    University of California, San Francisco

    See if you can join NCT03774758 on ClinicalTrials.gov

  12. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Locations
    17 in total
    Run by
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

  13. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California at San Francisco, San Francisco, California
    Locations
    15 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

  14. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California
    Locations
    26 in total
    Run by
    Frontier Medicines Corporation

    See if you can join NCT06244771 on ClinicalTrials.gov

  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, San Francisco, California
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  16. A Study of IBI363 in Subjects with Advanced Solid Malignancies

    This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California, San Francisco (UCSF), San Francisco, California
    Locations
    9 in total
    Run by
    Innovent Biologics (Suzhou) Co. Ltd.

    See if you can join NCT06281678 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.